You are here

Topic 372: Development and Validation of Non- Mouse Reagents to Enable Preclinical Development of Novel Therapeutics

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 75N91018C00041-0-0-0
Agency Tracking Number: N43CA180041
Amount: $299,854.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: N/A
Timeline
Solicitation Year: 2017
Award Year: 2018
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
10151 Pacific Mesa Blvd,
SAN DIEGO, CA 92121
United States
DUNS: 186489899
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Xiaomin Fan
 (858) 768-8107
 xfan@avantgen.com
Business Contact
 Xiaomin Fan
Phone: (858) 768-8107
Email: xfan@avantgen.com
Research Institution
N/A
Abstract

There is an increasing appreciation that dogs with naturally occurring cancers may be a better model system for evaluating cancer therapeutics than the traditional mouse model systems. However, use of dogs for evaluating the emerging class of immunotherapeutics for oncology is limited by the availability of suitable reagents to mentor the response of the canine immune system. The majority of reagents for canine markers that are currently available are rabbit polyclonal reagents, which are not renewable and suffer from lot-to-lot variability. In this Phase I study we propose to use our proprietary yeast antibody display platform to generate rabbit monoclonal antibodies (mAbs) against 3 canine markers, CD3e, PD-L 1 and IFN-gamma to demonstrate the power of our approach to generate high affinity, highly specific rabbit mAbs. In parallel we plan to screen our existing fully-human antibody libraries to isolate a function-blocking anti-canine PD-1 Antibody that also cross-reads with human PD-1 as a prototypic canine immunotherapeutic to be used in Phase II to assess in vivo immune responses using all the reagents generated during this project A successful outcome will result in a panel of high quality, well characterized and renewable reagents for canine biomarkers that will facilitate future development of immunotherapeutics.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government